PT1755391E - Métodos e composições para o tratamento de neuropatias - Google Patents
Métodos e composições para o tratamento de neuropatias Download PDFInfo
- Publication number
- PT1755391E PT1755391E PT57902835T PT05790283T PT1755391E PT 1755391 E PT1755391 E PT 1755391E PT 57902835 T PT57902835 T PT 57902835T PT 05790283 T PT05790283 T PT 05790283T PT 1755391 E PT1755391 E PT 1755391E
- Authority
- PT
- Portugal
- Prior art keywords
- compositions
- methods
- treating neuropathies
- neuropathies
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Diabetes (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US57723304P | 2004-06-04 | 2004-06-04 | |
US64133005P | 2005-01-04 | 2005-01-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT1755391E true PT1755391E (pt) | 2016-02-03 |
Family
ID=35782237
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT57902835T PT1755391E (pt) | 2004-06-04 | 2005-06-03 | Métodos e composições para o tratamento de neuropatias |
PT151930682T PT3006040T (pt) | 2004-06-04 | 2005-06-03 | Métodos e composições para o tratamento de neuropatias |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT151930682T PT3006040T (pt) | 2004-06-04 | 2005-06-03 | Métodos e composições para o tratamento de neuropatias |
Country Status (10)
Country | Link |
---|---|
US (4) | US7776326B2 (pt) |
EP (2) | EP1755391B1 (pt) |
JP (1) | JP2008501343A (pt) |
CN (1) | CN1964627B (pt) |
AU (1) | AU2005257883A1 (pt) |
CA (1) | CA2567848A1 (pt) |
DK (1) | DK1755391T3 (pt) |
ES (2) | ES2557810T3 (pt) |
PT (2) | PT1755391E (pt) |
WO (1) | WO2006001982A2 (pt) |
Families Citing this family (136)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8914114B2 (en) | 2000-05-23 | 2014-12-16 | The Feinstein Institute For Medical Research | Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation |
US7977049B2 (en) * | 2002-08-09 | 2011-07-12 | President And Fellows Of Harvard College | Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms |
AU2004253579B2 (en) * | 2003-07-01 | 2010-12-23 | Biomol International L.P. | Sirt1 modulators for manipulating cells/organism lifespan/stress response |
US20060025337A1 (en) * | 2003-07-01 | 2006-02-02 | President And Fellows Of Harvard College | Sirtuin related therapeutics and diagnostics for neurodegenerative diseases |
WO2005065667A2 (en) | 2003-12-29 | 2005-07-21 | President And Fellows Of Harvard College | Compositions for treating or preventing obesity and insulin resistance disorders |
US8017634B2 (en) * | 2003-12-29 | 2011-09-13 | President And Fellows Of Harvard College | Compositions for treating obesity and insulin resistance disorders |
US20050227327A1 (en) * | 2004-02-10 | 2005-10-13 | Brenner Charles M | Nicotinamide riboside kinase compositions and methods for using the same |
JP2007530586A (ja) | 2004-03-25 | 2007-11-01 | ザ ファインスタイン インスティテュート フォー メディカル リサーチ | 神経性止血法 |
US10912712B2 (en) | 2004-03-25 | 2021-02-09 | The Feinstein Institutes For Medical Research | Treatment of bleeding by non-invasive stimulation |
US20070212395A1 (en) * | 2006-03-08 | 2007-09-13 | Allergan, Inc. | Ocular therapy using sirtuin-activating agents |
CN1964627B (zh) * | 2004-06-04 | 2011-10-19 | 华盛顿大学 | 治疗神经病变的方法和组合物 |
WO2006004722A2 (en) * | 2004-06-30 | 2006-01-12 | Biomol Research Laboratories, Inc. | Compositions and methods for selectively activating human sirtuins |
AU2005323463B2 (en) * | 2004-12-27 | 2009-11-19 | The Feinstein Institutes For Medical Research | Treating inflammatory disorders by electrical vagus nerve stimulation |
US11207518B2 (en) * | 2004-12-27 | 2021-12-28 | The Feinstein Institutes For Medical Research | Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway |
AU2006204699B2 (en) * | 2005-01-13 | 2012-04-26 | Sirtris Pharmaceuticals, Inc. | Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders |
US20070014833A1 (en) * | 2005-03-30 | 2007-01-18 | Sirtris Pharmaceuticals, Inc. | Treatment of eye disorders with sirtuin modulators |
WO2006105440A2 (en) * | 2005-03-30 | 2006-10-05 | Sirtris Pharmaceuticals, Inc. | Nicotinamide riboside and analogues thereof |
US20060270614A1 (en) * | 2005-05-24 | 2006-11-30 | Sekhar Boddupalli | Use of chalcones for the treatment of viral disorders |
CA2609549A1 (en) * | 2005-05-25 | 2006-11-30 | Sirtris Pharmaceuticals, Inc. | Treatment of eye disorders with sirtuin modulators |
US20060292099A1 (en) * | 2005-05-25 | 2006-12-28 | Michael Milburn | Treatment of eye disorders with sirtuin modulators |
WO2006138418A2 (en) * | 2005-06-14 | 2006-12-28 | President And Fellows Of Harvard College | Improvement of cognitive performance with sirtuin activators |
US20070149466A1 (en) * | 2005-07-07 | 2007-06-28 | Michael Milburn | Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders |
AU2007244978B2 (en) | 2006-04-24 | 2013-05-30 | Allergan, Inc. | Abnormal Cannabidiols as agents for lowering intraocular pressure |
US7612101B2 (en) | 2006-04-24 | 2009-11-03 | Allergan, Inc. | Abnormal cannabidiols as agents for lowering intraocular pressure |
US7718830B2 (en) | 2006-04-24 | 2010-05-18 | Allergan, Inc. | Abnormal cannabidiols as agents for lowering intraocular pressure |
US7618966B2 (en) | 2006-04-24 | 2009-11-17 | Allergan, Inc. | Abnormal Cannabidiols as agents for lowering intraocular pressure |
EP2084141A4 (en) * | 2006-10-30 | 2010-07-21 | Novogen Res Pty Ltd | PREVENTION AND REVERSION OF CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY |
EP2124985A4 (en) * | 2007-01-26 | 2011-06-08 | Univ Washington | METHOD AND COMPOSITIONS FOR TREATING NERVOUS ELEMENTS |
CL2008001821A1 (es) * | 2007-06-20 | 2009-03-13 | Sirtris Pharmaceuticals Inc | Compuestos derivados de imidazo[2,1-b]-tiazol; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de diabetes, sindrome metabolico, resistencia a la insulina, entre otras. |
US20090005324A1 (en) * | 2007-06-29 | 2009-01-01 | Rong-Tsun Wu | Biologically active extract from dendrobium plant, use thereof and process for preparing the same |
US8391970B2 (en) * | 2007-08-27 | 2013-03-05 | The Feinstein Institute For Medical Research | Devices and methods for inhibiting granulocyte activation by neural stimulation |
WO2009054994A2 (en) * | 2007-10-23 | 2009-04-30 | President And Fellows Of Harvard College | Sirt-3 related methods and compositions for mimicking exercise |
WO2009108999A1 (en) | 2008-03-03 | 2009-09-11 | Ross Stewart Grant | Pharmaceutical formulations of resveratrol and methods of use thereof for treating cell disorders |
US9662490B2 (en) | 2008-03-31 | 2017-05-30 | The Feinstein Institute For Medical Research | Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug |
US9211409B2 (en) | 2008-03-31 | 2015-12-15 | The Feinstein Institute For Medical Research | Methods and systems for reducing inflammation by neuromodulation of T-cell activity |
EP2355893B1 (en) | 2008-11-18 | 2013-12-25 | Setpoint Medical Corporation | Devices for optimizing electrode placement for anti-inflamatory stimulation |
US20110054569A1 (en) * | 2009-09-01 | 2011-03-03 | Zitnik Ralph J | Prescription pad for treatment of inflammatory disorders |
US8996116B2 (en) * | 2009-10-30 | 2015-03-31 | Setpoint Medical Corporation | Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction |
US9211410B2 (en) | 2009-05-01 | 2015-12-15 | Setpoint Medical Corporation | Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation |
CN102573986B (zh) | 2009-06-09 | 2016-01-20 | 赛博恩特医疗器械公司 | 用于无导线刺激器的具有袋部的神经封套 |
US11051744B2 (en) | 2009-11-17 | 2021-07-06 | Setpoint Medical Corporation | Closed-loop vagus nerve stimulation |
US9833621B2 (en) | 2011-09-23 | 2017-12-05 | Setpoint Medical Corporation | Modulation of sirtuins by vagus nerve stimulation |
WO2011081945A2 (en) * | 2009-12-14 | 2011-07-07 | Cornell University | Activation and activators of sirt6 |
CN105126248B (zh) | 2009-12-23 | 2018-06-12 | 赛博恩特医疗器械公司 | 用于治疗慢性炎症的神经刺激设备和系统 |
KR20110097100A (ko) * | 2010-02-24 | 2011-08-31 | 전북대학교산학협력단 | 프리온 질병의 치료 및 예방에 효과를 갖는 레스베라트롤 |
GB201006961D0 (en) * | 2010-04-27 | 2010-06-09 | Babraham Inst | NMN modulator |
WO2012004917A1 (ja) * | 2010-07-06 | 2012-01-12 | Kaminishi Hidenori | 神経突起伸長剤 |
CA3128549A1 (en) | 2010-07-12 | 2012-01-19 | Universitat Autonoma De Barcelona | Gene therapy composition for use in diabetes treatment |
IT1406221B1 (it) * | 2010-12-13 | 2014-02-14 | Mkpharma Srl | Composizione contenente resveratrolo l/triptofano acido l/aspartico e vitamina b3 (nad+) per l'impiego in campo farmaceutico nutrizionale e cosmetico |
US20140065099A1 (en) * | 2011-02-15 | 2014-03-06 | Ecole Polytechnique Federale De Lausanne (Epfl) | Methods of Treating Mitochondrial Dysfunction |
CA2832234A1 (en) * | 2011-04-15 | 2012-10-18 | Nestec S.A. | Methods for regulating sirtuin gene expression |
WO2012154865A2 (en) | 2011-05-09 | 2012-11-15 | Setpoint Medical Corporation | Single-pulse activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation |
US20120328526A1 (en) * | 2011-06-27 | 2012-12-27 | University Of Maryland, Baltimore | Modulation of Nad+ Activity in Neuropathophysiological Conditions and Uses Thereof |
EP2726477A4 (en) * | 2011-06-29 | 2015-08-26 | Harvard College | SMALL MOLECULAR CD38 HEMMER AND USE METHOD THEREFOR |
JP6284475B2 (ja) * | 2011-06-29 | 2018-02-28 | ザ ジェネラル ホスピタル コーポレイション | 雌性生殖細胞における生体エネルギー状態を増強するための組成物及び方法 |
EP2574339A1 (de) | 2011-09-27 | 2013-04-03 | Johannes Huber | Pharmazeutisches Präparat zur Behandlung von NADH-bedingten Erkrankungen |
US9572983B2 (en) | 2012-03-26 | 2017-02-21 | Setpoint Medical Corporation | Devices and methods for modulation of bone erosion |
WO2014019108A1 (zh) * | 2012-07-28 | 2014-02-06 | 深圳华大基因研究院 | Nmnat1突变基因、检测其的引物、试剂盒和方法以及其用途 |
US20150265642A1 (en) * | 2012-10-09 | 2015-09-24 | President And Fellows Of Harvard College | Nad biosynthesis and precursors in the prevention and treatment of inflammation |
US9877981B2 (en) | 2012-10-09 | 2018-01-30 | President And Fellows Of Harvard College | NAD biosynthesis and precursors for the treatment and prevention of cancer and proliferation |
CN103054850A (zh) * | 2013-01-08 | 2013-04-24 | 赤峰学院附属医院 | 松属素在制备治疗神经退行性疾病药物中的用途 |
US8992951B2 (en) | 2013-01-09 | 2015-03-31 | Sapna Life Sciences Corporation | Formulations, procedures, methods and combinations thereof for reducing or preventing the development, or the risk of development, of neuropathology as a result of trauma |
EP4233878A1 (en) * | 2013-03-15 | 2023-08-30 | Washington University | Administration of nicotinamide mononucleotide in the treatment of dry eye |
WO2015044292A1 (en) * | 2013-09-26 | 2015-04-02 | Universitat Autonoma De Barcelona | Gene therapy compositions for use in the prevention and/or treatment of non-alcoholic fatty liver disease |
CN105873937A (zh) | 2013-10-30 | 2016-08-17 | 可劳迈戴斯有限公司 | 用于在治疗皮肤病中局部使用的烟酰胺核苷组合物 |
US20160279161A1 (en) * | 2013-11-14 | 2016-09-29 | Newsouth Innovation Pty Limited | Senescence and senescence associated secretory phenotype |
WO2015094532A1 (en) * | 2013-12-17 | 2015-06-25 | Mjn U.S. Holdings Llc | Nutritional composition containing a neurologic component of kaempferol and/or fisetin |
US20150297508A1 (en) * | 2014-04-21 | 2015-10-22 | William Andriette | Topical Formulation to Enhance Genital Sensation and Function |
CN106715455A (zh) | 2014-06-06 | 2017-05-24 | 葛兰素史密斯克莱知识产权(第2 号)有限公司 | 烟酰胺核苷类似物及其药物组合物和用途 |
EP3670522B1 (en) | 2014-07-24 | 2022-01-19 | W.R. Grace & CO. - CONN. | Crystalline form of nicotinamide riboside chloride |
WO2016041588A1 (en) | 2014-09-16 | 2016-03-24 | Universitat Autònoma De Barcelona | Adeno-associated viral vectors for the gene therapy of metabolic diseases |
US20160089383A1 (en) * | 2014-09-29 | 2016-03-31 | Everbloom, Llc | Nutritional supplements |
US11311725B2 (en) | 2014-10-24 | 2022-04-26 | Setpoint Medical Corporation | Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation |
WO2016086088A2 (en) * | 2014-11-25 | 2016-06-02 | Northwestern University | Wound healing through sirt1 overexpression |
WO2016122832A1 (en) * | 2015-01-30 | 2016-08-04 | Natural Formulations | Compositions, therapeutic and prophylactic methods for treatment of neurodegenerative diseases and brain injuries |
WO2016126807A1 (en) | 2015-02-03 | 2016-08-11 | Setpoint Medical Corporation | Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator |
CA2978069C (en) | 2015-03-09 | 2021-10-12 | W.R. Grace & Co.-Conn. | Crystalline form of nicotinamide riboside |
WO2016149395A1 (en) | 2015-03-16 | 2016-09-22 | ChromaDex Inc. | Nicotinic acid riboside or nicotinamide riboside compositions, reduced derivatives thereof, and the use thereof |
CN104814974A (zh) * | 2015-03-16 | 2015-08-05 | 邦泰生物工程(深圳)有限公司 | 烟酰胺单核苷酸在制备抗衰老药物或保健品的应用 |
CN104758307A (zh) * | 2015-03-16 | 2015-07-08 | 邦泰生物工程(深圳)有限公司 | Nadh和nmn在制备帕金森病药物或保健品的应用 |
JP6545256B2 (ja) * | 2015-03-31 | 2019-07-17 | 新興和製薬株式会社 | レスベラトロールとニコチンアミドモノヌクレオチドを含む食品組成物 |
CA2984379C (en) * | 2015-04-28 | 2024-06-11 | Newsouth Innovations Pty Limited | Targeting nad+ to treat chemotherapy and radiotherapy induced cognitive impairment, neuropathies, and inactivity |
US20180177703A1 (en) * | 2015-06-25 | 2018-06-28 | N.V. Perricone Llc | Niacinamide Mononucleotide Formulations For Skin Aging |
US11559421B2 (en) | 2015-06-25 | 2023-01-24 | Hill-Rom Services, Inc. | Protective dressing with reusable phase-change material cooling insert |
CA2994553C (en) | 2015-08-05 | 2022-08-30 | Metro International Biotech, Llc | Nicotinamide mononucleotide derivatives and their uses |
WO2017030167A1 (ja) * | 2015-08-18 | 2017-02-23 | レジリオ株式会社 | 神経回路網の再構築・賦活剤 |
GB2542881B (en) | 2015-10-02 | 2020-01-01 | Carr Andrew | Crystal forms of ß-nicotinamide mononucleotide |
CN108883105B (zh) * | 2015-10-23 | 2022-07-15 | 杰克逊实验室 | 烟酰胺用于治疗和预防眼部神经退行性疾病如青光眼 |
CN106659729A (zh) * | 2015-12-11 | 2017-05-10 | 邦泰生物工程(深圳)有限公司 | 烟酰胺单核苷酸在制备防治动脉硬化、心脑血管疾病的药物中的应用及其药物 |
US20170165283A1 (en) * | 2015-12-11 | 2017-06-15 | Bontac Bio-Engineering (Shenzhen) Co., Ltd | Use of beta-nicotinamide mononucleotide in preparation of health-care products for preventing and treating arteriosclerosis and cardio-cerebrovascular diseases, and health-care product containing the same |
US10596367B2 (en) | 2016-01-13 | 2020-03-24 | Setpoint Medical Corporation | Systems and methods for establishing a nerve block |
US11471681B2 (en) | 2016-01-20 | 2022-10-18 | Setpoint Medical Corporation | Batteryless implantable microstimulators |
CN108882885A (zh) | 2016-01-20 | 2018-11-23 | 赛博恩特医疗器械公司 | 迷走神经刺激的控制 |
WO2017127758A1 (en) | 2016-01-20 | 2017-07-27 | Setpoint Medical Corporation | Implantable microstimulators and inductive charging systems |
US10583304B2 (en) | 2016-01-25 | 2020-03-10 | Setpoint Medical Corporation | Implantable neurostimulator having power control and thermal regulation and methods of use |
ES2971878T3 (es) | 2016-02-22 | 2024-06-10 | Univ Pennsylvania | NR o NMN para mejorar la regeneración del hígado |
CA3021022C (en) * | 2016-04-14 | 2024-04-23 | ChromaDex Inc. | Use of nicotinamide riboside, nicotinic acid riboside, nicotinamide mononucleotide, and nicotinoyl compound derivatives in infant formula |
ES2948968T3 (es) | 2016-04-20 | 2023-09-22 | Chromadex Inc | Uso del ribósido de ácido nicotínico o derivados del ribósido de nicotinamida, y derivados reducidos de los mismos, como precursores que aumentan el NAD++ |
JP7067745B2 (ja) * | 2016-06-21 | 2022-05-16 | スフェラ ファーマ ピーブイティー リミテッド | (+)-エピカテキン及びその類似体の有用性 |
JP7090336B2 (ja) * | 2016-08-08 | 2022-06-24 | 慶應義塾 | Nad関連代謝産物の利用 |
MX2019002211A (es) | 2016-08-22 | 2019-10-30 | Elysium Health Inc | Composiciones de nicotinamida ribosido y pterostilbeno y metodos para el tratamiento de trastornos neurodegenerativos. |
EP3513795B1 (en) | 2016-09-13 | 2023-07-19 | Megumi Tanaka | Visual function improvement agent, and method for improving visual function |
US10689411B2 (en) | 2016-11-11 | 2020-06-23 | The Queen's University Of Belfast | Efficient and scalable syntheses of nicotinoyl ribosides and reduced nicotinoyl ribosides, modified derivatives thereof, phosphorylated analogs thereof, adenylyl dinucleotide conjugates thereof, and novel crystalline forms thereof |
AU2017367092B2 (en) | 2016-11-29 | 2022-11-03 | University Of Iowa Research Foundation | Use of NAD precursors for improving maternal health and/or offspring health |
US11071747B2 (en) | 2016-11-29 | 2021-07-27 | University Of Iowa Research Foundation | Use of NAD precursors for breast enhancement |
JP2020504722A (ja) * | 2016-12-21 | 2020-02-13 | ニューサウス イノベーションズ ピーティーワイ リミテッド | 血管密度を増加させる方法 |
US11879133B2 (en) | 2017-04-24 | 2024-01-23 | The Trustees Of The University Of Pennsylvania | Gene therapy for ocular disorders |
TW201919647A (zh) * | 2017-08-10 | 2019-06-01 | 華盛頓大學 | 使用菸鹼醯胺單核苷酸之組成物及治療方法 |
EP3668402B1 (en) | 2017-08-14 | 2024-07-31 | Setpoint Medical Corporation | Vagus nerve stimulation pre-screening test |
JP7072825B2 (ja) * | 2017-09-13 | 2022-05-23 | 三菱電機ソフトウエア株式会社 | コピー数計測装置、コピー数計測プログラムおよびコピー数計測方法 |
EP3682746A4 (en) * | 2017-09-14 | 2021-03-10 | Megumi Tanaka | AGING PROTECTION AGENTS AND AGING PROTECTION PROCEDURES |
US11103465B2 (en) | 2017-11-22 | 2021-08-31 | Ted's Brain Science, Inc. | Trans-resveratrol topical medication for the treatment of pain and method of manufacture thereof |
CA3086535A1 (en) | 2017-12-22 | 2019-06-27 | Elysium Health, Inc. | Crystalline forms of nicotinamide riboside chloride |
US11180521B2 (en) | 2018-01-30 | 2021-11-23 | Metro International Biotech, Llc | Nicotinamide riboside analogs, pharmaceutical compositions, and uses thereof |
KR20210153027A (ko) * | 2018-09-14 | 2021-12-16 | 메구미 타나카 | 노화방지제 및 노화방지방법 |
US11260229B2 (en) | 2018-09-25 | 2022-03-01 | The Feinstein Institutes For Medical Research | Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation |
CA3116729C (en) * | 2018-10-19 | 2024-05-28 | Disarm Therapeutics, Inc. | Inhibitors of sarm1 in combination with nad+ or a nad+ precursor |
CN109925308A (zh) * | 2018-12-29 | 2019-06-25 | 广东宏盈科技有限公司 | 异黄酮在制备治疗眼底黄斑病变的药物中的应用 |
US20220160688A1 (en) * | 2019-03-20 | 2022-05-26 | The Johns Hopkins University | Inhibition of nampt and/or sarm1 for the treatment of axonal degradation |
US11939348B2 (en) | 2019-03-22 | 2024-03-26 | Metro International Biotech, Llc | Compositions comprising a phosphorus derivative of nicotinamide riboside and methods for modulation of nicotinamide adenine dinucleotide |
US10618927B1 (en) | 2019-03-22 | 2020-04-14 | Metro International Biotech, Llc | Compositions and methods for modulation of nicotinamide adenine dinucleotide |
WO2021013795A2 (en) | 2019-07-19 | 2021-01-28 | Biosynth Ag | Method of making nicotinamide ribofuranoside salts, nicotinamide ribofuranoside salts as such, and uses thereof |
CN110507695A (zh) * | 2019-08-20 | 2019-11-29 | 泓博元生命科技(深圳)有限公司 | Nadh和/或nmn在制备脑功能恢复的药物、保健品中的应用 |
CN113117083A (zh) * | 2019-12-31 | 2021-07-16 | 刘永政 | 提升哺乳动物Sirtuin蛋白家族活性的物质的应用 |
FR3106056B1 (fr) * | 2020-01-13 | 2021-12-17 | Nuvamid | Utilisation de NMN pour la prévention et/ou le traitement d’une douleur articulaire induite par l’activité physique et compositions correspondantes |
MX2022011177A (es) * | 2020-03-11 | 2022-12-13 | Massachusetts Eye & Ear Infirmary | Terapia genica para la degeneracion de la retina asociada a nmnat1. |
JPWO2021187396A1 (pt) * | 2020-03-16 | 2021-09-23 | ||
KR20230012585A (ko) | 2020-05-21 | 2023-01-26 | 더 파인스타인 인스티튜츠 포 메디칼 리서치 | 미주 신경 자극을 위한 시스템들 및 방법들 |
CN112245446A (zh) * | 2020-10-20 | 2021-01-22 | 合肥康诺生物制药有限公司 | Nad在制备治疗阿尔兹海默症药物中的用途 |
ES2974212T3 (es) * | 2020-12-18 | 2024-06-26 | Nuvamid Sa | Derivados de mononucleótidos de nicotinamida en el tratamiento y la prevención de la enfermedad de células falciformes |
CN112675152A (zh) * | 2020-12-25 | 2021-04-20 | 厦门金达威生物科技有限公司 | 一种nmn缓释肠溶性微胶囊及其制备方法 |
MX2023013903A (es) * | 2021-05-27 | 2023-12-11 | Metro Int Biotech Llc | Solidos cristalinos de mononucleotido de acido nicotinico y esteres de estos y metodos de elaboracion y uso. |
JP2023005922A (ja) * | 2021-06-29 | 2023-01-18 | 株式会社常磐植物化学研究所 | サーチュイン活性化剤 |
CN114045288A (zh) * | 2021-10-21 | 2022-02-15 | 浙江大学 | 靶向敲降SIRT2基因的shRNA及烟酰胺腺嘌呤二核苷酸的前体在制备治疗神经退行性疾病的药物中的应用 |
WO2024100421A1 (en) | 2022-11-12 | 2024-05-16 | Cambridge Enterprise Limited | Sarm1 inhibitors for use in therapy and cosmetics |
WO2024170772A1 (en) * | 2023-02-17 | 2024-08-22 | Mim Neurosciences Ab | Epigallocatechin-3-gallate (egcg) analogs for use in the treatment of diseases in which an increase of nad+ is beneficial such as glaucoma |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5856329A (en) * | 1995-06-28 | 1999-01-05 | Allergan | Method of using (2-imidazolin-2-ylamino) quinoxalines in treating ocular neural injury |
EP0848707B1 (fr) * | 1995-09-08 | 1999-08-04 | Synthelabo | Derives de 4-(cycloalkyl)piperidines et de 4-(cycloalkylalkyl)pi peridines, leur preparation et leur application en therapeutique |
TR200001149T2 (tr) * | 1997-10-28 | 2000-08-21 | Unilever N.V. | Oda sıcaklığında niteliği bozulmayan niteliği bozulmayan ve esası çay olan bir içecek |
EP1076691A1 (en) | 1998-04-28 | 2001-02-21 | Mitokor | Cellular and animal models for diseases associated with altered mitochondrial function |
CA2374612A1 (en) | 1999-05-28 | 2000-12-07 | Immunex Corporation | Novel murine and human kinases |
US6573299B1 (en) | 1999-09-20 | 2003-06-03 | Advanced Medical Instruments | Method and compositions for treatment of the aging eye |
CN1270034A (zh) | 1999-11-04 | 2000-10-18 | 第一军医大学珠江医院 | 辅酶在组织细胞化学和辐射损伤防治中的应用 |
US6821775B1 (en) | 2000-02-11 | 2004-11-23 | Genvec, Inc. | Viral vector encoding pigment epithelium-derived factor |
US6964969B2 (en) | 2001-04-19 | 2005-11-15 | Mccleary Edward Larry | Composition and method for treating impaired or deteriorating neurological function |
FR2842424A1 (fr) * | 2002-07-22 | 2004-01-23 | Univ Paris 7 Denis Diderot | Utilisation du nad ou de l'un de ses analogues, substrat des mono-adp-ribosyl tranferases, pour la preparation d'un medicament destine au traitement des pathologies liees aux recepteurs purinergiques |
US7977049B2 (en) * | 2002-08-09 | 2011-07-12 | President And Fellows Of Harvard College | Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms |
CA2421269A1 (en) * | 2002-08-09 | 2004-02-09 | President And Fellows Of Harvard College | Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms |
US20050080024A1 (en) * | 2002-08-15 | 2005-04-14 | Joseph Tucker | Nitric oxide donating derivatives for the treatment of cardiovascular disorders |
US20060025337A1 (en) * | 2003-07-01 | 2006-02-02 | President And Fellows Of Harvard College | Sirtuin related therapeutics and diagnostics for neurodegenerative diseases |
AU2004253579B2 (en) | 2003-07-01 | 2010-12-23 | Biomol International L.P. | Sirt1 modulators for manipulating cells/organism lifespan/stress response |
WO2005004814A2 (en) * | 2003-07-02 | 2005-01-20 | Elixir Pharmaceuticals, Inc. | Sirt1 and genetic disorders |
US20050227327A1 (en) * | 2004-02-10 | 2005-10-13 | Brenner Charles M | Nicotinamide riboside kinase compositions and methods for using the same |
WO2005077091A2 (en) * | 2004-02-10 | 2005-08-25 | Trustees Of Dartmouth College | Nicotinamide riboside kinase compositions and methods for using the same |
CN1964627B (zh) * | 2004-06-04 | 2011-10-19 | 华盛顿大学 | 治疗神经病变的方法和组合物 |
JP2008528510A (ja) * | 2005-01-20 | 2008-07-31 | サートリス ファーマシューティカルズ, インコーポレイテッド | 紅潮および/または薬物誘発性体重増加を処置するためのサーチュイン活性化化合物の使用 |
JP2009503117A (ja) * | 2005-08-04 | 2009-01-29 | サートリス ファーマシューティカルズ, インコーポレイテッド | サーチュインモジュレーターとしてのベンゾイミダゾール誘導体 |
-
2005
- 2005-06-03 CN CN2005800181148A patent/CN1964627B/zh active Active
- 2005-06-03 PT PT57902835T patent/PT1755391E/pt unknown
- 2005-06-03 EP EP05790283.5A patent/EP1755391B1/en active Active
- 2005-06-03 PT PT151930682T patent/PT3006040T/pt unknown
- 2005-06-03 WO PCT/US2005/019524 patent/WO2006001982A2/en not_active Application Discontinuation
- 2005-06-03 CA CA002567848A patent/CA2567848A1/en not_active Abandoned
- 2005-06-03 ES ES05790283.5T patent/ES2557810T3/es active Active
- 2005-06-03 AU AU2005257883A patent/AU2005257883A1/en not_active Abandoned
- 2005-06-03 ES ES15193068.2T patent/ES2663226T3/es active Active
- 2005-06-03 EP EP15193068.2A patent/EP3006040B1/en active Active
- 2005-06-03 DK DK05790283.5T patent/DK1755391T3/en active
- 2005-06-03 US US11/144,358 patent/US7776326B2/en active Active
- 2005-06-03 JP JP2007515603A patent/JP2008501343A/ja active Pending
-
2010
- 2010-05-28 US US12/790,722 patent/US8889126B2/en active Active
-
2014
- 2014-10-10 US US14/511,701 patent/US9295688B2/en active Active
-
2016
- 2016-03-11 US US15/067,449 patent/US20160199401A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1755391B1 (en) | 2015-11-11 |
DK1755391T3 (en) | 2016-02-08 |
WO2006001982A2 (en) | 2006-01-05 |
CN1964627A (zh) | 2007-05-16 |
US20100272702A1 (en) | 2010-10-28 |
AU2005257883A1 (en) | 2006-01-05 |
US20160199401A1 (en) | 2016-07-14 |
US9295688B2 (en) | 2016-03-29 |
ES2663226T3 (es) | 2018-04-11 |
US20060002914A1 (en) | 2006-01-05 |
WO2006001982A3 (en) | 2006-08-17 |
EP3006040B1 (en) | 2017-11-22 |
PT3006040T (pt) | 2018-03-28 |
EP1755391A4 (en) | 2010-03-10 |
US20150038560A1 (en) | 2015-02-05 |
EP3006040A1 (en) | 2016-04-13 |
US8889126B2 (en) | 2014-11-18 |
CA2567848A1 (en) | 2006-01-05 |
US7776326B2 (en) | 2010-08-17 |
ES2557810T3 (es) | 2016-01-28 |
JP2008501343A (ja) | 2008-01-24 |
CN1964627B (zh) | 2011-10-19 |
EP1755391A2 (en) | 2007-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1755391A4 (en) | METHODS AND COMPOSITIONS FOR TREATING NEUROPATHIES | |
HK1216080A1 (zh) | 用於治療或預防草酸鹽相關疾病的組合物和方法 | |
HK1121952A1 (en) | Methods and compositions for treating conditions | |
GB2423928B (en) | Methods and compositions for treating pain | |
EP1737482A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES | |
IL180844A0 (en) | Compositions and methods for treating excessive bleeding | |
IL184047A0 (en) | Methods and compositions for treating amyloid-related diseases | |
EP1732650A4 (en) | COMPOSITION AND METHOD FOR CANCER TREATMENT | |
EP1959929A4 (en) | COMPOSITIONS AND METHODS FOR TREATING DERMATOLOGICAL SUFFERING | |
IL176919A0 (en) | Methods and compositions for treating cancer | |
IL176259A0 (en) | Compositions and methods for treating diabetes | |
IL186963A0 (en) | Methods and compositions for treating pain | |
EP2124985A4 (en) | METHOD AND COMPOSITIONS FOR TREATING NERVOUS ELEMENTS | |
IL185056A0 (en) | Compositions and methods for treating or preventing flaviviridae infections | |
EP1890712A4 (en) | COMPOSITIONS AND METHODS FOR TREATING PAIN | |
EP1940437A4 (en) | COMPOSITIONS AND METHOD FOR THE TREATMENT OF BACTERIA | |
ZA200708575B (en) | Methods and compositions for treating or preventing cancer | |
EP1755537A4 (en) | METHOD AND COMPOSITIONS FOR PREVENTING OR TREATING PERIODONTOPATHIA | |
ZA200608932B (en) | Method and compositions for epilation | |
EP1855662A4 (en) | METHODS AND COMPOSITIONS FOR TREATING CANCER | |
IL184062A0 (en) | Visco-supplement composition and methods | |
ZA200605722B (en) | Composition and method | |
ZA200706038B (en) | Visco-supplement composition and methods | |
GB0419175D0 (en) | Method of treatment and compositions | |
EP1796712A4 (en) | METHOD AND COMPOSITIONS FOR TREATING HYPERCHOLESTEROLEMIA |